Intarcia Therapeutics, Inc.

ACTIVE

610 Main St, 加利福尼亚州阿拉梅达县, California, United Stateswww.intarcia.comPrivate251–500 employeesEstablished: 1997-01-01

Clinical Trials

17 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1997

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

38.9%

Trial Status Distribution

Active, not recruiting

94.4%

Completed

5.6%

Clinical Trials

Trials sponsored by this organization (18)

A Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Comparators Empagliflozin and Glimepiride in Patients with Type 2 Diabetes that are on Metformin Therapy

Phase 1

Active, not recruiting

May 2017930 participants

A Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Comparators Empagliflozin and Glimepiride in Patients with Type 2 Diabetes that are on Metformin Therapy

Phase 1

Active, not recruiting

Apr 2017930 participants

A Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Comparators Empagliflozin and Glimepiride in Patients with Type 2 Diabetes that are on Metformin Therapy

Phase 1

Active, not recruiting

Apr 2017930 participants

A Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes

Active, not recruiting

Jul 20143,000 participants

A Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes

Phase 1

Active, not recruiting

Jul 20134,000 participants

A Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes

Active, not recruiting

Jun 20133,000 participants

A Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes

Phase 1

Active, not recruiting

Apr 20133,000 participants

A Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes

Active, not recruiting

Feb 20134,000 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations